Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELOXX PHARMACEUTICALS, INC.

(ELOX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/22/2021 10/25/2021 10/26/2021 10/27/2021 10/28/2021 Date
1.33(c) 1.36(c) 1.36(c) 1.34(c) 1.32 Last
654 143 802 212 237 206 300 438 6 735 Volume
-7.64% +2.26% 0.00% -1.47% -1.49% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -67,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,30x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -47,0 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,34x
Yield 2022 -
Capitalization 116 M 116 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 25
Free-Float 90,4%
More Financials
Company
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing ribonucleic acid (RNA)-modulating drug candidates, each designed to be a eukaryotic ribosomal selective glycoside (ERSG), formulated to treat rare and ultra-rare premature stop codon diseases. The Company's lead product candidate, ELX-02, is a small molecule designed to restore production of full-length... 
More about the company
Ratings of Eloxx Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
C
More Ratings
All news about ELOXX PHARMACEUTICALS, INC.
10/12ELOXX PHARMACEUTICALS : Webcast and Conference Call
PU
10/07ELOXX PHARMACEUTICALS : to Host Investor and Analyst Call and Webcast on Cystic Fibrosis P..
GL
10/05ELOXX PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Termination of a..
AQ
10/05HERCULES CAPITAL : Eloxx Pharmaceuticals Secures Debt Facility of Up to $30 Million from H..
AQ
10/05Eloxx Pharmaceuticals Secures Debt Facility of Up to $30 Million from Hercules Capital
CI
09/30ELOXX PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Other Events, Fi..
AQ
09/30Eloxx Pharmaceuticals, Inc. announced that it expects to receive $30 million in funding..
CI
09/13ELOXX PHARMACEUTICALS, INC. : Regulation FD Disclosure (form 8-K)
AQ
09/09Eloxx Pharmaceuticals 15% Higher After FDA Fast Track Designation
DJ
09/09ELOXX PHARMACEUTICALS' : ELX-02 Receives US FDA Fast-Track Designation to Treat Cystic Fib..
MT
09/09ELOXX PHARMACEUTICALS : Announces Fast Track Designation for ELX-02 for the Treatment of C..
AQ
09/09Eloxx Pharmaceuticals Announces Fast Track Designation for ELX-02 for the Treatment of ..
CI
09/09Eloxx Pharmaceuticals Gets FDA Fast Track Designation for ELX-02 in Cystic Fibrosis
DJ
09/08ELOXX PHARMACEUTICALS : Appoints Chief Medical Officer
AQ
09/08Eloxx Pharmaceuticals, Inc. Appoints Ali Hariri as Chief Medical Officer
CI
More news
News in other languages on ELOXX PHARMACEUTICALS, INC.
09/09ELX-02 d'Eloxx Pharmaceuticals reçoit la désignation de procédure accélérée de la FDA p..
More news
Analyst Recommendations on ELOXX PHARMACEUTICALS, INC.
More recommendations
Chart ELOXX PHARMACEUTICALS, INC.
Duration : Period :
Eloxx Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELOXX PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 1,34 $
Average target price 3,78 $
Spread / Average Target 182%
EPS Revisions
Managers and Directors
Sumit Aggarwal President, Chief Executive Officer & Director
Daniel E. Geffken Chief Financial & Accounting Officer
Tomer Kariv Chairman
Vijay Modur Head-Research & Development
Ali Hariri Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ELOXX PHARMACEUTICALS, INC.-66.33%116
MODERNA, INC.226.29%137 595
LONZA GROUP AG32.74%61 065
IQVIA HOLDINGS INC.41.93%48 579
SEAGEN INC.-0.30%31 768
CELLTRION, INC.-39.00%25 528